Emmanouil Sinakos
Overview
Explore the profile of Emmanouil Sinakos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
580
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liava C, Chourmouzi D, Sinakos E, Dimitroulas T, Navrozidou C, Akriviadis E
Dig Dis Sci
. 2025 Feb;
PMID: 39946067
Background: A positive family history is considered the strongest recognizable risk factor for developing inflammatory bowel diseases (IBD) and is present in 8-12% of cases. Aims: To determine the prevalence...
2.
Malandris K, Korakas E, Sarakapina A, Kalopitas G, Iatridi F, Liakos A, et al.
Dig Dis Sci
. 2024 Dec;
70(2):814-824.
PMID: 39708259
Aim: Controlled attenuation parameter (CAP) enables the noninvasive diagnosis of liver steatosis. Magnetic resonance imaging proton density fat fraction (MRI-PDFF) is increasingly used over biopsy for the assessment of steatosis...
3.
Malandris K, Katsoula A, Liakos A, Karagiannis T, Sinakos E, Giouleme O, et al.
Diabetes Obes Metab
. 2024 Dec;
27(3):1406-1414.
PMID: 39703127
Aims: A novel noninvasive score, Agile-4 score, combining liver stiffness measurements, aspartate aminotransferase/alanine aminotransferase, platelet count, diabetes status and sex has been developed for the identification of cirrhosis in patients...
4.
Malandris K, Arampidis D, Mainou M, Papadopoulos N, Karagiannis T, Nayfeh T, et al.
J Gastroenterol Hepatol
. 2024 Oct;
39(12):2582-2591.
PMID: 39394945
Background And Aim: Following the approval of the first agent for the management of metabolic dysfunction-associated steatohepatitis (MASH), identification of patients with fibrotic MASH (MASH with NAS ≥ 4 and...
5.
Malandris K, Katsoula A, Liakos A, Bekiari E, Karagiannis T, Theocharidou E, et al.
Ann Gastroenterol
. 2024 Sep;
37(5):579-587.
PMID: 39238800
Background: The controlled attenuation parameter (CAP) enables the noninvasive assessment of liver steatosis. We performed a systematic review and meta-analysis to evaluate the diagnostic accuracy of CAP for identifying liver...
6.
Fragkou N, Vlachaki E, Goulis I, Sinakos E
World J Hepatol
. 2024 May;
16(5):671-677.
PMID: 38818299
In this Editorial, we highlight the possible role that metabolism dysfunction-associated steatotic liver disease (MASLD) may play in the future, regarding liver disease in patients with transfusion-dependent β-thalassemia (TDBT). MASLD...
7.
Malandris K, Papandreou S, Vasilakou D, Kakotrichi P, Sarakapina A, Kalopitas G, et al.
J Gastroenterol Hepatol
. 2024 Apr;
39(7):1219-1229.
PMID: 38627972
Background And Aim: Several agents are under investigation for nonalcoholic fatty liver disease (NAFLD). We assessed the comparative efficacy of pharmacologic interventions for patients with NAFLD focusing on magnetic resonance...
8.
Cholongitas E, Oikonomou T, Bafa K, Sinakos E, Papatheodoridis G, Goulis I
Transplantation
. 2024 Apr;
108(9):e239-e244.
PMID: 38557857
Background: The use of nucleos(t)ide analogs (NAs) with a high genetic barrier to resistance, namely entecavir and tenofovir, has improved the efficacy of antiviral prophylaxis against hepatitis B virus (HBV)...
9.
Sinakos E, Kachru N, Tsoulas C, Jeyakumar S, Smith N, Yehoshua A, et al.
J Comp Eff Res
. 2024 Feb;
13(4):e230090.
PMID: 38317634
This study assessed the clinical impact and cost-effectiveness of switching from tenofovir disoproxil fumarate (TDF) to either tenofovir alafenamide (TAF) or entecavir (ETV) in a Greek chronic hepatitis B (CHB)...
10.
Malandris K, Papandreou S, Avgerinos I, Karagiannis T, Paschos P, Michailidis T, et al.
Hormones (Athens)
. 2023 Sep;
22(4):655-664.
PMID: 37770761
Purpose: To assess the comparative efficacy of glucose-lowering drugs on liver steatosis as assessed by means of magnetic resonance imaging (MRI) in patients with T2D. Methods: We searched several databases...